The three discrete [Zn 6 ] c omplexes [Na 3 Zn 6 (cpdp) 3 (μ-Bz) 3 (CH 3 OH) 6 ][ZnCl 4 ][ZnCl 3 (H 2 O)]• 3CH 3 OH•1.5H 2 O (1), [Na 3 Zn 6 (cpdp) 3 (μ-p-OBz) 3 (CH 3 OH) 6 ]• 2H 2 O (2), and [Na 3 Zn 6, have been successfully synthesized and fully characterized (Bz = benzoate; p-OBz = dianion of phydroxybenzoic acid; p-NO 2 Bz = p-nitrobenzoate). The complexes have been characterized by elemental analysis, FTIR, UV−vis, NMR spectroscopy, PXRD, and thermal analysis, including singlecrystal X-ray crystallography of 1 and 2. The molecular architectures of 1−3 are built from the self-assembly of their corresponding [Zn 2 ] units, which are interconnected to the central [Na 3 (CH 3 OH) 6 ] 3+ core by six endogenous benzoate groups, with each linking one Zn(II) and one Na(I) ion in a μ 2 :η 1 :η 1 -syn-anti bidentate fashion. The composition of the (cpdp 3− ) 3 /(Zn 2+ ) 6 complexes in 1−3 has been observed to be 1:2, on the basis of the UV−vis titration and NMR spectroscopic results, which is further supported by Xray crystallography. Systematic biological studies performed with a mice model suggested possible antidiabetic efficacy as well as anticancer activities of the complexes. When complexes 1−3 were administered intraperitoneally in mice, 1 showed a lowering in the blood glucose level, overall maintenance of the pancreatic tissue mass, restriction of DNA damage in pancreatic cells, and retention of lipid droplet (LD) frequency, whereas 2 and 3 showed hepatic tissue mass consistency by inhibiting the DNA damage in hepatic cells, prior to the exposure to a potent diabetic inducer, alloxan (ALX). Similar trends of results were observed in inhibiting the generation of reactive oxygen species (ROS) in the pancreatic and hepatic cells, as examined by spectrofluorometric methods. Thus, 1 seems to be a better compound for overall diabetic management and control, whereas 2 and 3 seem to be promising compounds for designing chemopreventive drugs against hepatic carcinoma.